Business
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizing Molecular Diagnostics: Transforming Transplant Success.” Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) In the episode, James discussed iMDx’s mission, the company’s focus on transplant diagnostics, and its strategy to brin
About this update from Insight Molecular Diagnostics Inc.
[{"type":"image","alt":"Empowered Patient Podcast","displaySize":"","headline":null,"caption":"Empowered Patient Podcast","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7e86f26b84a49be90801d6531df18238"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M8wTHgeaIrNrw9GvPySWeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7e86f26b84a49be90801d6531df18238","width":300,"height":300}},"lazy":false},{"type":"text","content":"BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizing Molecular Diagnostics: Transforming Transplant Success.”","length":296,"tagName":"p"},{"type":"image","alt":"Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx)","displaySize":"","headline":null,"caption":"Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx)","className":"","disableSlideshowImg":false,"size":{"original":{"width":322,"height":230,"url":"https://media.zenfs.com/en/globenewswire.com/ea11fd1f44b93d9b532aea6a4a3523d7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0GAwe7ROsk3DRjVIGIamhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea11fd1f44b93d9b532aea6a4a3523d7","width":322,"height":230}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx)","length":83,"tagName":"p"},{"type":"text","content":"In the episode, James discussed iMDx’s mission, the company’s focus on transplant diagnostics, and its strategy to bring testing closer to patients by developing kits that hospitals can run themselves. She also highlighted ongoing clinical development, the regulatory pathway to FDA clearance, and the company’s broader vision of democratizing access to molecular diagnostics both in the U.S. and globally.","length":406,"tagName":"p"},{"type":"text","content":"In June, the company changed its name from Oncocyte to Insight Molecular Diagnostics Inc., or iMDx, with a mission to democratize access to novel molecular diagnostic testing to...